Raloxifene - Addpharma
Alternative Names: AD 101- Addpharma; AD-101Latest Information Update: 31 Dec 2021
Price :
$50 *
At a glance
- Originator Addpharma
- Class Antineoplastics; Calcium regulators; Osteoporosis therapies; Small molecules; Stilbenes
- Mechanism of Action Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Postmenopausal osteoporosis
Most Recent Events
- 17 Dec 2020 Raloxifene - Addpharma is available for licensing as of 17 Dec 2020. http://www.addpharma.co.kr/
- 08 Feb 2019 Addpharma completes a phase I pharmacokinetic trial for Postmenopausal osteoporosis (In volunteers) in South Korea (PO) (NCT03764462)
- 05 Dec 2018 Phase-I clinical trials in Postmenopausal osteoporosis (In volunteers) in South Korea (PO) (NCT03764462)